Role of skin ultrasound in diagnosis of systemic sclerosis compared to Modified Rodnan skin score, inflammatory marker and disease activity indices

Document Type : Original Article

Authors

1 Internal medicine department, Faculty of Medicine, Beni-Suef University, Egypt

2 Radiology department , Faculty of Medicine, Beni-Suef University, Egypt

Abstract

The  goal of  this study  To assess if  high frequency ultrasound correlates with modified Rodnan skin score  and inflammatory markers and  if  it can differentiate between Systemic sclerosis and  healthy individuals and  if  HFU can detect subclinical skin thickening.  We recruited 30 consecutive patients with SSc and  40  controls  in this case control study. Skin thickness was measured by 20-22 MHz ultrasonic probe at 3 different skin sites bilaterally (at third proximal interphalyngeal, third  metacarpophalyngeal and wrist joints bilaterally). Total skin thickness (TST) by HFU and skin thickness using mRSS were recorded and compared to HFU.
The final results of our work show that total skin thickness  in patients with  SSc was higher than in healthy controls (P < 0.001), and correlated positively with total mRSS and correlated negatively with CRP. Patients with higher TST had  higher  mRSS . The area under the receiver operator characteristic (ROC) curve yielded sensitivity of 90% and specificity of 85% at the predicted probability of 1.4 mm as the optimal cut off  point to access  of  mean skin thickness.

Keywords

Main Subjects

References

  1. Sapadin AN, Esser AC, FleischmajerR.Immunopathogenesis of scleroderma– evolving concepts. Mt Sinai J Med. 2001;68:233–42.
  2. Denton CP, Khanna D. Systemic sclerosis. Lancet 2017.pii: S0140‑673630933‑9.
  3. Czirják L, Foeldvari I, Müller‑Ladner U. Skin involvementin systemic sclerosis. Rheumatology (Oxford) 2008;47Suppl 5:v44‑5.
  4. Amjadi S, Maranian P, Furst D, et al.Course of the modified Rodnan skin thicknessscore in systemic sclerosis clinical trials: analysis of three large multicenter, doubleblind,randomized controlled trials. Arthritis Rheum. 2009;60:2490–8.
  5. Khanna D, Furst DE, Clements PJ, et al. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. JScleroderma RelatDisord. 2017;2:11–8.
  6. Kaldas M, Khanna PP, Furst DE, et al.Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis–assessment of individual body sites in two large randomized controlled trials. Rheumatology(Oxford). 2009;48:1143–6.
  7. Jordan S, Distler JH, Maurer B, et al.Effects and safety of rituximab insystemic sclerosis: an analysis from the European scleroderma trial andresearch (EUSTAR) group. Ann Rheum Dis. 2015;74:1188–94.
  8. Jung M, Bonner A, Hudson M, et al. Myopathy is a poor prognostic featurein systemic sclerosis: results from the Canadian Scleroderma ResearchGroup (CSRG) cohort. Scand J Rheumatol. 2014;43:217–20.
  9. Robinson P. Sonography of common tendon injuries. Am J Rev 2009;193:607–618.4
  10. Rubin JM, Bude RO, Carson PL, Bree RL, Adler RS. Power Doppler US: apotentially useful alternative to mean frequency-based color Doppler US.Radiology 1994; 190:853–856.
  11. Hongyan Li1, Daniel E. Furst2, H et al Department of Immunology and Rheumatology, the Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China 2018
  12. Liu H, Hou Y, Zhu Q-l, Xu D, Wang L, Li J- c, et al. (2017) A preliminary study of skinultrasound in diffuse cutaneous systemic sclerosis: e0174481.
  13. hesselstrand,A.scheja, M.wildat et al.,2007 Dpartment of rheumatology, lund university  hospital ,lund ,Sweden.
Egyptian Journal of Medical Research
Volume 4, Issue 1
January 2023
Pages 57-68

Files

Share

How to cite

Statistics